The global Live and Attenuated Vaccine market was valued at million in 2024 and is projected to reach US$ million by 2031, at a CAGR of %during the forecast period.
The U.S. market size is estimated at $ million in 2024, while China is to reach $ million.
Pediatric Vaccine segment will reach $ million by 2031, with a % CAGR in next six years.
The global key manufacturers of Live and Attenuated Vaccine include GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc, Johnson & Johnson, CSL Limited, Emergent BioSolutions, Inc., MedImmune, LLC, Sanofi, Serum Institute, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Live and Attenuated Vaccine manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Live and Attenuated Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live and Attenuated Vaccine. This report contains market size and forecasts of Live and Attenuated Vaccine in global, including the following market information:
Global Live and Attenuated Vaccine market revenue, 2020-2025, 2026-2031, ($ millions)
Global Live and Attenuated Vaccine market sales, 2020-2025, 2026-2031, (K Units)
Global top five Live and Attenuated Vaccine companies in 2024 (%)
Total Market by Segment:
Global Live and Attenuated Vaccine market, by Type, 2020-2025, 2026-2031 ($ millions) & (K Units)
Global Live and Attenuated Vaccine market segment percentages, by Type, 2024 (%)
Pediatric Vaccine
Adult Vaccines
Global Live and Attenuated Vaccine market, by Application, 2020-2025, 2026-2031 ($ Millions) & (K Units)
Global Live and Attenuated Vaccine market segment percentages, by Application, 2024 (%)
Hospitals
Clinics
Diagnostic Centers
Research Institute
Others
Global Live and Attenuated Vaccine market, by region and country, 2020-2025, 2026-2031 ($ millions) & (K Units)
Global Live and Attenuated Vaccine market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Live and Attenuated Vaccine revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Live and Attenuated Vaccine revenues share in global market, 2024 (%)
Key companies Live and Attenuated Vaccine sales in global market, 2020-2025 (estimated), (K Units)
Key companies Live and Attenuated Vaccine sales share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Merck & Co.
Pfizer, Inc
Astellas Pharma Inc
Johnson & Johnson
CSL Limited
Emergent BioSolutions, Inc.
MedImmune, LLC
Sanofi
Serum Institute
Outline of Major Chapters:
Chapter 1: Introduces the definition of Live and Attenuated Vaccine, market overview.
Chapter 2: Global Live and Attenuated Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Live and Attenuated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Live and Attenuated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Live and Attenuated Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Live and Attenuated Vaccine Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Live and Attenuated Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Live and Attenuated Vaccine Overall Market Size
2.1 Global Live and Attenuated Vaccine Market Size: 2024 VS 2031
2.2 Global Live and Attenuated Vaccine Market Size, Prospects & Forecasts: 2020-2031
2.3 Global Live and Attenuated Vaccine Sales: 2020-2031
3 Company Landscape
3.1 Top Live and Attenuated Vaccine Players in Global Market
3.2 Top Global Live and Attenuated Vaccine Companies Ranked by Revenue
3.3 Global Live and Attenuated Vaccine Revenue by Companies
3.4 Global Live and Attenuated Vaccine Sales by Companies
3.5 Global Live and Attenuated Vaccine Price by Manufacturer (2020-2025)
3.6 Top 3 and Top 5 Live and Attenuated Vaccine Companies in Global Market, by Revenue in 2024
3.7 Global Manufacturers Live and Attenuated Vaccine Product Type
3.8 Tier 1, Tier 2, and Tier 3 Live and Attenuated Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Live and Attenuated Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Live and Attenuated Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 Segment by Type - Global Live and Attenuated Vaccine Market Size Markets, 2024 & 2031
4.1.2 Pediatric Vaccine
4.1.3 Adult Vaccines
4.2 Segment by Type - Global Live and Attenuated Vaccine Revenue & Forecasts
4.2.1 Segment by Type - Global Live and Attenuated Vaccine Revenue, 2020-2025
4.2.2 Segment by Type - Global Live and Attenuated Vaccine Revenue, 2026-2031
4.2.3 Segment by Type - Global Live and Attenuated Vaccine Revenue Market Share, 2020-2031
4.3 Segment by Type - Global Live and Attenuated Vaccine Sales & Forecasts
4.3.1 Segment by Type - Global Live and Attenuated Vaccine Sales, 2020-2025
4.3.2 Segment by Type - Global Live and Attenuated Vaccine Sales, 2026-2031
4.3.3 Segment by Type - Global Live and Attenuated Vaccine Sales Market Share, 2020-2031
4.4 Segment by Type - Global Live and Attenuated Vaccine Price (Manufacturers Selling Prices), 2020-2031
5 Sights by Application
5.1 Overview
5.1.1 Segment by Application - Global Live and Attenuated Vaccine Market Size, 2024 & 2031
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Diagnostic Centers
5.1.5 Research Institute
5.1.6 Others
5.2 Segment by Application - Global Live and Attenuated Vaccine Revenue & Forecasts
5.2.1 Segment by Application - Global Live and Attenuated Vaccine Revenue, 2020-2025
5.2.2 Segment by Application - Global Live and Attenuated Vaccine Revenue, 2026-2031
5.2.3 Segment by Application - Global Live and Attenuated Vaccine Revenue Market Share, 2020-2031
5.3 Segment by Application - Global Live and Attenuated Vaccine Sales & Forecasts
5.3.1 Segment by Application - Global Live and Attenuated Vaccine Sales, 2020-2025
5.3.2 Segment by Application - Global Live and Attenuated Vaccine Sales, 2026-2031
5.3.3 Segment by Application - Global Live and Attenuated Vaccine Sales Market Share, 2020-2031
5.4 Segment by Application - Global Live and Attenuated Vaccine Price (Manufacturers Selling Prices), 2020-2031
6 Sights by Region
6.1 By Region - Global Live and Attenuated Vaccine Market Size, 2024 & 2031
6.2 By Region - Global Live and Attenuated Vaccine Revenue & Forecasts
6.2.1 By Region - Global Live and Attenuated Vaccine Revenue, 2020-2025
6.2.2 By Region - Global Live and Attenuated Vaccine Revenue, 2026-2031
6.2.3 By Region - Global Live and Attenuated Vaccine Revenue Market Share, 2020-2031
6.3 By Region - Global Live and Attenuated Vaccine Sales & Forecasts
6.3.1 By Region - Global Live and Attenuated Vaccine Sales, 2020-2025
6.3.2 By Region - Global Live and Attenuated Vaccine Sales, 2026-2031
6.3.3 By Region - Global Live and Attenuated Vaccine Sales Market Share, 2020-2031
6.4 North America
6.4.1 By Country - North America Live and Attenuated Vaccine Revenue, 2020-2031
6.4.2 By Country - North America Live and Attenuated Vaccine Sales, 2020-2031
6.4.3 United States Live and Attenuated Vaccine Market Size, 2020-2031
6.4.4 Canada Live and Attenuated Vaccine Market Size, 2020-2031
6.4.5 Mexico Live and Attenuated Vaccine Market Size, 2020-2031
6.5 Europe
6.5.1 By Country - Europe Live and Attenuated Vaccine Revenue, 2020-2031
6.5.2 By Country - Europe Live and Attenuated Vaccine Sales, 2020-2031
6.5.3 Germany Live and Attenuated Vaccine Market Size, 2020-2031
6.5.4 France Live and Attenuated Vaccine Market Size, 2020-2031
6.5.5 U.K. Live and Attenuated Vaccine Market Size, 2020-2031
6.5.6 Italy Live and Attenuated Vaccine Market Size, 2020-2031
6.5.7 Russia Live and Attenuated Vaccine Market Size, 2020-2031
6.5.8 Nordic Countries Live and Attenuated Vaccine Market Size, 2020-2031
6.5.9 Benelux Live and Attenuated Vaccine Market Size, 2020-2031
6.6 Asia
6.6.1 By Region - Asia Live and Attenuated Vaccine Revenue, 2020-2031
6.6.2 By Region - Asia Live and Attenuated Vaccine Sales, 2020-2031
6.6.3 China Live and Attenuated Vaccine Market Size, 2020-2031
6.6.4 Japan Live and Attenuated Vaccine Market Size, 2020-2031
6.6.5 South Korea Live and Attenuated Vaccine Market Size, 2020-2031
6.6.6 Southeast Asia Live and Attenuated Vaccine Market Size, 2020-2031
6.6.7 India Live and Attenuated Vaccine Market Size, 2020-2031
6.7 South America
6.7.1 By Country - South America Live and Attenuated Vaccine Revenue, 2020-2031
6.7.2 By Country - South America Live and Attenuated Vaccine Sales, 2020-2031
6.7.3 Brazil Live and Attenuated Vaccine Market Size, 2020-2031
6.7.4 Argentina Live and Attenuated Vaccine Market Size, 2020-2031
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Live and Attenuated Vaccine Revenue, 2020-2031
6.8.2 By Country - Middle East & Africa Live and Attenuated Vaccine Sales, 2020-2031
6.8.3 Turkey Live and Attenuated Vaccine Market Size, 2020-2031
6.8.4 Israel Live and Attenuated Vaccine Market Size, 2020-2031
6.8.5 Saudi Arabia Live and Attenuated Vaccine Market Size, 2020-2031
6.8.6 UAE Live and Attenuated Vaccine Market Size, 2020-2031
7 Manufacturers & Brands Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Live and Attenuated Vaccine Major Product Offerings
7.1.4 GlaxoSmithKline Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.1.5 GlaxoSmithKline Key News & Latest Developments
7.2 Merck & Co.
7.2.1 Merck & Co. Company Summary
7.2.2 Merck & Co. Business Overview
7.2.3 Merck & Co. Live and Attenuated Vaccine Major Product Offerings
7.2.4 Merck & Co. Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.2.5 Merck & Co. Key News & Latest Developments
7.3 Pfizer, Inc
7.3.1 Pfizer, Inc Company Summary
7.3.2 Pfizer, Inc Business Overview
7.3.3 Pfizer, Inc Live and Attenuated Vaccine Major Product Offerings
7.3.4 Pfizer, Inc Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.3.5 Pfizer, Inc Key News & Latest Developments
7.4 Astellas Pharma Inc
7.4.1 Astellas Pharma Inc Company Summary
7.4.2 Astellas Pharma Inc Business Overview
7.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Major Product Offerings
7.4.4 Astellas Pharma Inc Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.4.5 Astellas Pharma Inc Key News & Latest Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Company Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Live and Attenuated Vaccine Major Product Offerings
7.5.4 Johnson & Johnson Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.5.5 Johnson & Johnson Key News & Latest Developments
7.6 CSL Limited
7.6.1 CSL Limited Company Summary
7.6.2 CSL Limited Business Overview
7.6.3 CSL Limited Live and Attenuated Vaccine Major Product Offerings
7.6.4 CSL Limited Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.6.5 CSL Limited Key News & Latest Developments
7.7 Emergent BioSolutions, Inc.
7.7.1 Emergent BioSolutions, Inc. Company Summary
7.7.2 Emergent BioSolutions, Inc. Business Overview
7.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Major Product Offerings
7.7.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.7.5 Emergent BioSolutions, Inc. Key News & Latest Developments
7.8 MedImmune, LLC
7.8.1 MedImmune, LLC Company Summary
7.8.2 MedImmune, LLC Business Overview
7.8.3 MedImmune, LLC Live and Attenuated Vaccine Major Product Offerings
7.8.4 MedImmune, LLC Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.8.5 MedImmune, LLC Key News & Latest Developments
7.9 Sanofi
7.9.1 Sanofi Company Summary
7.9.2 Sanofi Business Overview
7.9.3 Sanofi Live and Attenuated Vaccine Major Product Offerings
7.9.4 Sanofi Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.9.5 Sanofi Key News & Latest Developments
7.10 Serum Institute
7.10.1 Serum Institute Company Summary
7.10.2 Serum Institute Business Overview
7.10.3 Serum Institute Live and Attenuated Vaccine Major Product Offerings
7.10.4 Serum Institute Live and Attenuated Vaccine Sales and Revenue in Global (2020-2025)
7.10.5 Serum Institute Key News & Latest Developments
8 Global Live and Attenuated Vaccine Production Capacity, Analysis
8.1 Global Live and Attenuated Vaccine Production Capacity, 2020-2031
8.2 Live and Attenuated Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Live and Attenuated Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Live and Attenuated Vaccine Supply Chain Analysis
10.1 Live and Attenuated Vaccine Industry Value Chain
10.2 Live and Attenuated Vaccine Upstream Market
10.3 Live and Attenuated Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Live and Attenuated Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
List of Tables
Table 1. Key Players of Live and Attenuated Vaccine in Global Market
Table 2. Top Live and Attenuated Vaccine Players in Global Market, Ranking by Revenue (2024)
Table 3. Global Live and Attenuated Vaccine Revenue by Companies, (US$, Mn), 2020-2025
Table 4. Global Live and Attenuated Vaccine Revenue Share by Companies, 2020-2025
Table 5. Global Live and Attenuated Vaccine Sales by Companies, (K Units), 2020-2025
Table 6. Global Live and Attenuated Vaccine Sales Share by Companies, 2020-2025
Table 7. Key Manufacturers Live and Attenuated Vaccine Price (2020-2025) & (US$/Unit)
Table 8. Global Manufacturers Live and Attenuated Vaccine Product Type
Table 9. List of Global Tier 1 Live and Attenuated Vaccine Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Live and Attenuated Vaccine Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segment by Type – Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2024 & 2031
Table 12. Segment by Type - Global Live and Attenuated Vaccine Revenue (US$, Mn), 2020-2025
Table 13. Segment by Type - Global Live and Attenuated Vaccine Revenue (US$, Mn), 2026-2031
Table 14. Segment by Type - Global Live and Attenuated Vaccine Sales (K Units), 2020-2025
Table 15. Segment by Type - Global Live and Attenuated Vaccine Sales (K Units), 2026-2031
Table 16. Segment by Application – Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2024 & 2031
Table 17. Segment by Application - Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 18. Segment by Application - Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 19. Segment by Application - Global Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 20. Segment by Application - Global Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 21. By Region – Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2025-2031
Table 22. By Region - Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 23. By Region - Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 24. By Region - Global Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 25. By Region - Global Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 26. By Country - North America Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 27. By Country - North America Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 28. By Country - North America Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 29. By Country - North America Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 30. By Country - Europe Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 31. By Country - Europe Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 32. By Country - Europe Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 33. By Country - Europe Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 34. By Region - Asia Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 35. By Region - Asia Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 36. By Region - Asia Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 37. By Region - Asia Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 38. By Country - South America Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 39. By Country - South America Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 40. By Country - South America Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 41. By Country - South America Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 42. By Country - Middle East & Africa Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2025
Table 43. By Country - Middle East & Africa Live and Attenuated Vaccine Revenue, (US$, Mn), 2026-2031
Table 44. By Country - Middle East & Africa Live and Attenuated Vaccine Sales, (K Units), 2020-2025
Table 45. By Country - Middle East & Africa Live and Attenuated Vaccine Sales, (K Units), 2026-2031
Table 46. GlaxoSmithKline Company Summary
Table 47. GlaxoSmithKline Live and Attenuated Vaccine Product Offerings
Table 48. GlaxoSmithKline Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 49. GlaxoSmithKline Key News & Latest Developments
Table 50. Merck & Co. Company Summary
Table 51. Merck & Co. Live and Attenuated Vaccine Product Offerings
Table 52. Merck & Co. Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 53. Merck & Co. Key News & Latest Developments
Table 54. Pfizer, Inc Company Summary
Table 55. Pfizer, Inc Live and Attenuated Vaccine Product Offerings
Table 56. Pfizer, Inc Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 57. Pfizer, Inc Key News & Latest Developments
Table 58. Astellas Pharma Inc Company Summary
Table 59. Astellas Pharma Inc Live and Attenuated Vaccine Product Offerings
Table 60. Astellas Pharma Inc Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 61. Astellas Pharma Inc Key News & Latest Developments
Table 62. Johnson & Johnson Company Summary
Table 63. Johnson & Johnson Live and Attenuated Vaccine Product Offerings
Table 64. Johnson & Johnson Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 65. Johnson & Johnson Key News & Latest Developments
Table 66. CSL Limited Company Summary
Table 67. CSL Limited Live and Attenuated Vaccine Product Offerings
Table 68. CSL Limited Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 69. CSL Limited Key News & Latest Developments
Table 70. Emergent BioSolutions, Inc. Company Summary
Table 71. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Offerings
Table 72. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 73. Emergent BioSolutions, Inc. Key News & Latest Developments
Table 74. MedImmune, LLC Company Summary
Table 75. MedImmune, LLC Live and Attenuated Vaccine Product Offerings
Table 76. MedImmune, LLC Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 77. MedImmune, LLC Key News & Latest Developments
Table 78. Sanofi Company Summary
Table 79. Sanofi Live and Attenuated Vaccine Product Offerings
Table 80. Sanofi Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 81. Sanofi Key News & Latest Developments
Table 82. Serum Institute Company Summary
Table 83. Serum Institute Live and Attenuated Vaccine Product Offerings
Table 84. Serum Institute Live and Attenuated Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 85. Serum Institute Key News & Latest Developments
Table 86. Live and Attenuated Vaccine Capacity of Key Manufacturers in Global Market, 2023-2025 (K Units)
Table 87. Global Live and Attenuated Vaccine Capacity Market Share of Key Manufacturers, 2023-2025
Table 88. Global Live and Attenuated Vaccine Production by Region, 2020-2025 (K Units)
Table 89. Global Live and Attenuated Vaccine Production by Region, 2026-2031 (K Units)
Table 90. Live and Attenuated Vaccine Market Opportunities & Trends in Global Market
Table 91. Live and Attenuated Vaccine Market Drivers in Global Market
Table 92. Live and Attenuated Vaccine Market Restraints in Global Market
Table 93. Live and Attenuated Vaccine Raw Materials
Table 94. Live and Attenuated Vaccine Raw Materials Suppliers in Global Market
Table 95. Typical Live and Attenuated Vaccine Downstream
Table 96. Live and Attenuated Vaccine Downstream Clients in Global Market
Table 97. Live and Attenuated Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Live and Attenuated Vaccine Product Picture
Figure 2. Live and Attenuated Vaccine Segment by Type in 2024
Figure 3. Live and Attenuated Vaccine Segment by Application in 2024
Figure 4. Global Live and Attenuated Vaccine Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Live and Attenuated Vaccine Market Size: 2024 VS 2031 (US$, Mn)
Figure 7. Global Live and Attenuated Vaccine Revenue: 2020-2031 (US$, Mn)
Figure 8. Live and Attenuated Vaccine Sales in Global Market: 2020-2031 (K Units)
Figure 9. The Top 3 and 5 Players Market Share by Live and Attenuated Vaccine Revenue in 2024
Figure 10. Segment by Type – Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2024 & 2031
Figure 11. Segment by Type - Global Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 12. Segment by Type - Global Live and Attenuated Vaccine Sales Market Share, 2020-2031
Figure 13. Segment by Type - Global Live and Attenuated Vaccine Price (US$/Unit), 2020-2031
Figure 14. Segment by Application – Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2024 & 2031
Figure 15. Segment by Application - Global Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 16. Segment by Application - Global Live and Attenuated Vaccine Sales Market Share, 2020-2031
Figure 17. Segment by Application -Global Live and Attenuated Vaccine Price (US$/Unit), 2020-2031
Figure 18. By Region – Global Live and Attenuated Vaccine Revenue, (US$, Mn), 2025 & 2031
Figure 19. By Region - Global Live and Attenuated Vaccine Revenue Market Share, 2020 VS 2024 VS 2031
Figure 20. By Region - Global Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 21. By Region - Global Live and Attenuated Vaccine Sales Market Share, 2020-2031
Figure 22. By Country - North America Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 23. By Country - North America Live and Attenuated Vaccine Sales Market Share, 2020-2031
Figure 24. United States Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 25. Canada Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 26. Mexico Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 27. By Country - Europe Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 28. By Country - Europe Live and Attenuated Vaccine Sales Market Share, 2020-2031
Figure 29. Germany Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 30. France Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 31. U.K. Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 32. Italy Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 33. Russia Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 34. Nordic Countries Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 35. Benelux Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 36. By Region - Asia Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 37. By Region - Asia Live and Attenuated Vaccine Sales Market Share, 2020-2031
Figure 38. China Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 39. Japan Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 40. South Korea Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 41. Southeast Asia Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 42. India Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 43. By Country - South America Live and Attenuated Vaccine Revenue Market Share, 2020-2031
Figure 44. By Country - South America Live and Attenuated Vaccine Sales, Market Share, 2020-2031
Figure 45. Brazil Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 46. Argentina Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 47. By Country - Middle East & Africa Live and Attenuated Vaccine Revenue, Market Share, 2020-2031
Figure 48. By Country - Middle East & Africa Live and Attenuated Vaccine Sales, Market Share, 2020-2031
Figure 49. Turkey Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 50. Israel Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 51. Saudi Arabia Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 52. UAE Live and Attenuated Vaccine Revenue, (US$, Mn), 2020-2031
Figure 53. Global Live and Attenuated Vaccine Production Capacity (K Units), 2020-2031
Figure 54. The Percentage of Production Live and Attenuated Vaccine by Region, 2024 VS 2031
Figure 55. Live and Attenuated Vaccine Industry Value Chain
Figure 56. Marketing Channels
